Yildiz Ayşegül
Dokuz Eylül U. Tip Fak., Psikiyatri AD., Izmir.
Turk Psikiyatri Derg. 2003 Summer;14(2):134-44.
Given the diversity of clinical entities from which agitation may arise, it is not surprising that it is among the most commonly encountered clinical problems in psychiatric facilities and hospital emergency services. However, quite surprisingly this area has received very little attention and has not been studied in clinical trials until recently. Thus, tremendous variability exists in approaches to agitation. In this work, we review what is known about the pharmacologic management of agitation; first, by examining published studies comparing conventional antipsychotics, benzodiazepines, and/or a combination of both to achieve calm in acutely agitated psychiatric patients; and second, by reviewing available data on the use of atypical antipsychotic medications for the acute treatment of agitation associated with psychiatric illness. In our first review, we identified 11 trials meeting our inclusion criteria, 8 with a blind design. These studies taken together suggest that combination treatment may be superior to either agent alone, with higher improvement rates and lower incidence of extrapyramidal side effects. In our review of atypical antipsychotic agents as acute antiagitation compounds, we identified 5 studies, 3 with a blind design. This review found atypical antipsychotics to be as effective as the classical ones and more advantageous. Based on the data available to date, among the present novel antipsychotic agents, ziprasidone, risperidone, and olanzapine seem to be the best acute antiagitation compounds.
鉴于可能引发激越的临床病症具有多样性,激越是精神科机构和医院急诊科最常遇到的临床问题之一也就不足为奇了。然而,颇为令人惊讶的是,这一领域一直很少受到关注,直到最近才在临床试验中得到研究。因此,在处理激越的方法上存在极大的差异。在这项工作中,我们回顾了关于激越的药物治疗的已知情况;首先,通过审视已发表的研究,这些研究比较了传统抗精神病药物、苯二氮䓬类药物和/或两者联合使用,以让急性激越的精神科患者平静下来;其次,通过回顾关于使用非典型抗精神病药物急性治疗与精神疾病相关的激越的现有数据。在我们的首次回顾中,我们确定了11项符合我们纳入标准的试验,其中8项采用了盲法设计。综合这些研究表明,联合治疗可能优于单独使用任何一种药物,改善率更高,锥体外系副作用的发生率更低。在我们对作为急性抗激越化合物的非典型抗精神病药物的回顾中,我们确定了5项研究,其中3项采用了盲法设计。这项回顾发现非典型抗精神病药物与经典药物一样有效且更具优势。根据目前可得的数据,在现有的新型抗精神病药物中,齐拉西酮、利培酮和奥氮平似乎是最佳的急性抗激越化合物。